Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes

Nature Chemical Biology

Volumn 3, Issue 10, 2007, Pages 668-677

  Blum, Galia ^a   Von Degenfeld, Georges ^a   Merchant, Milton J ^a   Blau, Helen M ^a   Bogyo, Matthew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CYSTEINE PROTEINASE; DIAGNOSTIC AGENT; GB 119; GB 123; GB 125; GB 135; GB 137; GB 138; K 11777; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HUMAN CELL; IMAGING SYSTEM; MALE; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WHOLE BODY IMAGING;

MUS;

EID: 34548666006     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2007.26     Document Type: Article

References (39)

1. Berger, A.B., Vitorino, P.M. & Bogyo, M. Activity-based protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am. J. Pharmacogenomics 4, 371-381 (2004).
2. Evans, M.J. & Cravatt, B.F. Mechanism-based profiling of enzyme families. Chem. Rev. 106, 3279-3301 (2006).
3. Sadaghiani, A.M., Verhelst, S.H. & Bogyo, M. Tagging and detection strategies for activity-based proteomics. Curr. Opin. Chem. Biol. 11, 20-28 (2006).
4. Saghatelian, A. & Cravatt, B.F. Assignment of protein function in the postgenomic era. Nat. Chem. Biol. 1, 130-142 (2005).
5. Schmidinger, H., Hermetter, A. & Birner-Gruenberger, R. Activity-based proteomics: enzymatic activity profiling in complex proteomes. Amino Acids 30, 333-350 (2006).
6. Greenbaum, D. et al. Chemical approaches for functionally probing the proteome. Mol. Cell. Proteomics 1, 60-68 (2002).
7. Patricelli, M.P., Giang, D.K., Stamp, L.M. & Burbaum, J.J. Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes. Proteomics 1, 1067-1071 (2001).
8. Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M. & Cravatt, B.F. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. USA 101, 10000-10005 (2004).
9. Sieber, S.A., Niessen, S., Hoover, H.S. & Cravatt, B.F. Proteomic profiling of metalloprotease activities with cocktails of active-site probes. Nat. Chem. Biol. 2, 274-281 (2006).
10. Lecaille, F., Kaleta, J. & Bromme, D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 102, 4459-4488 (2002).
11. Mueller-Steiner, S. et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51, 703-714 (2006).
12. Jedeszko, C. & Sloane, B.F. Cysteine cathepsins in human cancer. Biol. Chem. 385, 1017-1027 (2004).
13. Mohamed, M.M. & Sloane, B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 6, 764-775 (2006).
14. Foekens, J.A. et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J. Clin. Oncol. 16, 1013-1021 (1998).
15. Harbeck, N. et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin. Cancer Res. 7, 2757-2764 (2001).
16. Jagodic, M., Vrhovec, I., Borstnar, S. & Cufer, T. Prognostic and predictive value of cathepsins D and L in operable breast cancer patients. Neoplasma 52, 1-9 (2005).
17. Lah, T.T. et al. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators. Clin. Cancer Res. 6, 578-584 (2000).
18. Gocheva, V. et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20, 543-556 (2006).
19. Joyce, J.A. et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453 (2004).
20. Urbich, C. et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat. Med. 11, 206-213 (2005).
21. Vasiljeva, O. et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 66, 5242-5250 (2006).
22. Choy, G., Choyke, P. & Libutti, S.K. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol. Imaging 2, 303-312 (2003).
23. Licha, K. & Olbrich, C. Optical imaging in drug discovery and diagnostic applications. Adv. Drug Deliv. Rev. 57, 1087-1108 (2005).
24. Shah, K. & Weissleder, R. Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx 2, 215-225 (2005).
25. Baruch, A., Jeffery, D.A. & Bogyo, M. Enzyme activity-it's all about image. Trends Cell Biol. 14, 29-35 (2004).
26. Bremer, C. et al. Optical imaging of spontaneous breast tumors using protease sensing 'smart' optical probes. Invest. Radiol. 40, 321-327 (2005).
27. Jiang, T. et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. USA 101, 17867-17872 (2004).
28. Tung, C.H., Mahmood, U., Bredow, S. & Weissleder, R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 60, 4953-4958 (2000).
29. Weissleder, R., Tung, C.H., Mahmood, U. & Bogdanov, A., Jr In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol. 17, 375-378 (1999).
30. Blum, G. et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat. Chem. Biol. 1, 203-209 (2005).
31. Ledakis, P. et al. Cathepsins D, B, and L in malignant human lung tissue. Clin. Cancer Res. 2, 561-568 (1996).
32. D'Orazi, G. et al. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. J. Gene Med. 2, 11-21 (2000).
33. Jessani, N., Niessen, S., Mueller, B.M. & Cravatt, B.F. Breast cancer cell lines grown in vivo: what goes in isn't always the same as what comes out. Cell Cycle 4, 253-255 (2005).
34. Bogyo, M., Verhelst, S., Bellingard-Dubouchaud, V., Toba, S. & Greenbaum, D. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem. Biol. 7, 27-38 (2000).
35. Palmer, J.T., Rasnick, D., Klaus, J.L. & Bromme, D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 38, 3193-3196 (1995).
36. Smith, S.M., Kane, S.E., Gal, S., Mason, R.W. & Gottesman, M.M. Glycosylation of procathepsin L does not account for species molecular-mass differences and is not required for proteolytic activity. Biochem. J. 262, 931-938 (1989).
37. Coombs, G.S. et al. Substrate specificity of prostate-specific antigen (PSA). Chem. Biol. 5, 475-488 (1998).
38. Liu, S., Bugge, T.H. & Leppla, S.H. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J. Biol. Chem. 276, 17976-17984 (2001).
39. Kato, D. et al. Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1, 33-38 (2005).